| Literature DB >> 26440606 |
Farshad Falahati1, Daniel Ferreira2, Hilkka Soininen3, Patrizia Mecocci4, Bruno Vellas5, Magda Tsolaki6, Iwona Kłoszewska7, Simon Lovestone8,9, Maria Eriksdotter2, Lars-Olof Wahlund2, Andrew Simmons8,9, Eric Westman2.
Abstract
The similarity of atrophy patterns in Alzheimer's disease (AD) and in normal aging suggests age as a confounding factor in multivariate models that use structural magnetic resonance imaging (MRI) data. To study the effect and compare different age correction approaches on AD diagnosis and prediction of mild cognitive impairment (MCI) progression as well as investigate the characteristics of correctly and incorrectly classified subjects. Data from two multi-center cohorts were included in the study [AD = 297, MCI = 445, controls (CTL) = 340]. 34 cortical thickness and 21 subcortical volumetric measures were extracted from MRI. The age correction approaches involved: using age as a covariate to MRI-derived measures and linear detrending of age-related changes based on CTL measures. Orthogonal projections to latent structures was used to discriminate between AD and CTL subjects, and to predict MCI progression to AD, up to 36-months follow-up. Both age correction approaches improved models' quality in terms of goodness of fit and goodness of prediction, as well as classification and prediction accuracies. The observed age associations in classification and prediction results were effectively eliminated after age correction. A detailed analysis of correctly and incorrectly classified subjects highlighted age associations in other factors: ApoE genotype, global cognitive impairment and gender. The two methods for age correction gave similar results and show that age can partially masks the influence of other aspects such as cognitive impairment, ApoE-e4 genotype and gender. Age-related brain atrophy may have a more important association with these factors than previously believed.Entities:
Keywords: Age correction; Alzheimer’s disease; Diagnostic misclassification; Early diagnosis; MRI; Mild cognitive impairment; OPLS
Mesh:
Year: 2015 PMID: 26440606 PMCID: PMC4754326 DOI: 10.1007/s10548-015-0455-1
Source DB: PubMed Journal: Brain Topogr ISSN: 0896-0267 Impact factor: 3.020
Demographic and clinical characteristics
| CTL | MCI-s | MCI-pa | AD | |
|---|---|---|---|---|
| Count | 340 | 360 | 85 | 297 |
| Age, years | 75.0 ± 5.7 | 75.0 ± 6.9 | 74.3 ± 6.5 | 75.7 ± 7.0 |
| Gender, Female/Male | 172/168 | 141/219 | 35/50 | 165/132 |
| Education, years | 14.3 ± 4.3 | 13.9 ± 4.7 | 13.8 ± 4.2 | 12.0 ± 4.9 |
| MMSE score | 29.1 ± 1.1 | 27.1 ± 1.7 | 26.5 ± 1.8 | 22.2 ± 3.7 |
| CDR | 0 | 0.5 | 0.5 | 0.92 ± 0.43 |
| ApoE-e4, N/P | 242/92 | 182/158 | 31/52 | 110/178 |
| Cohort, ADNI/ANM | 227/113 | 260/100 | 62/23 | 175/122 |
Continuous data is represented as mean ± SD, CTL control subjects, MCI mild cognitive impairment, MCI-s stable MCI, MCI-p progressive MCI, AD Alzheimer’s disease, MMSE mini mental state examination, CDR clinical dementia rating, ApoE apolipoprotein E, N/P negative/positive for at least one e4 allele, ADNI/ANM Alzheimer’s Disease Neuroimaging Initiative/AddNeuroMed
aMCI patients progressed to AD at month-12 follow-up
AD classification and MCI prediction results
| Model | Q2 | R2 | Accuracy % | Sensitivity % | Specificity % | |
|---|---|---|---|---|---|---|
| AD versus CTL classification (CV) | Uncorrected | 0.567 | 0.568 | 86.7 | 81.8 | 90.9 |
| Covariate | 0.580 | 0.586 | 87.3 | 81.5 | 92.4 | |
| Detrended | 0.582 | 0.583 | 88.2 | 82.8 | 92.9 | |
| MCI prediction | Uncorrected | – | – | 62.7 | 70.2 | 60.9 |
| Covariate | – | – | 62.9 | 71.4 | 60.9 | |
| Detrended | – | – | 65.0 | 75.0 | 62.6 |
AD Alzheimer’s disease, CTL control subjects, MCI mild cognitive impairment, CV cross-validated, Q goodness of prediction, R goodness of fit
Fig. 1The blue, green and cyan markers represent the entorhinal cortex thickness of CTL, AD and MCI subjects before and after age correction with detrending method: a CTL subjects before age correction, b CTL subjects after age correction, c AD patients before age correction, d AD patients after age correction, e MCI patients before age correction and f MCI patients after age correction. Each marker corresponds to one subject. The red lines indicate the age-related drift fitted in the groups (Color figure online)
Prediction results for MCI subjects of ADNI cohort at different follow-up time points
| Time point | Model | Accuracy % | Sensitivity % | Specificity % |
|---|---|---|---|---|
| Month-12 | Uncorrected | 60.9 | 72.1 | 58.2 |
| Covariate | 60.2 | 70.5 | 57.9 | |
| Detrended | 63.0 | 75.4 | 60.2 | |
| Month-18 | Uncorrected | 64.9 | 72.2 | 62.1 |
| Covariate | 66.1 | 74.4 | 62.9 | |
| Detrended | 67.7 | 75.6 | 64.7 | |
| Month-24 | Uncorrected | 65.5 | 66.7 | 64.8 |
| Covariate | 67.4 | 69.0 | 66.3 | |
| Detrended | 68.9 | 69.8 | 68.4 | |
| Month-36 | Uncorrected | 66.8 | 65.3 | 68.0 |
| Covariate | 69.3 | 68.0 | 70.3 | |
| Detrended | 70.8 | 68.7 | 72.7 |
MCI mild cognitive impairment, MCI-s stable MCI, MCI-p progressive MCI
Subjects’ characteristics in AD versus CTL classification: comparison between correctly/incorrectly classified subjects
| AD versus CTL Classification | CTL subjects | AD patients | Incorrect-classified AD versus CTL | ||||
|---|---|---|---|---|---|---|---|
| Correct-classified | Incorrect-classified |
| Correct-classified | Incorrect-classified |
|
| |
|
| |||||||
| Count | 309 | 31 | 243 | 54 | |||
| Age, years | 74.5 ± 5.6 | 79.1 ± 5.2 |
| 76.2 ± 6.7 | 73.3 ± 7.9 |
|
|
| Education, years | 14.3 ± 4.3 | 14.1 ± 5.5 | 0.839a | 11.9 ± 4.8 | 12.8 ± 5.1 | 0.197a | 0.294a |
| MMSE score | 29.1 ± 1.1 | 28.9 ± 1.2 | 0.326a | 21.8 ± 3.7 | 24.2 ± 2.8 |
|
|
| Gender, Male/Female | 152/157 | 16/15 | 0.797b | 107/136 | 25/29 | 0.762b | 0.637b |
| ApoE-e4, N/P | 217/87 | 26/5 | 0.138b | 86/149 | 24/29 | 0.240b |
|
| Cohort, ADNI/ANM | 207/102 | 20/11 | 0.780b | 141/102 | 34/20 | 0.505b | 0.886b |
|
| |||||||
| Count | 314 | 26 | 242 | 55 | |||
| Age, years | 74.8 ± 5.7 | 77.0 ± 4.3 | 0.058a | 75.7 ± 6.8 | 75.4 ± 7.7 | 0.776a | 0.237a |
| Education, years | 14.2 ± 4.2 | 14.0 ± 5.6 | 0.781a | 11.9 ± 4.7 | 12.5 ± 5.3 | 0.412a | 0.269a |
| MMSE score | 29.1 ± 1.1 | 28.9 ± 1.1 | 0.326a | 21.7 ± 3.7 | 24.4 ± 2.7 |
|
|
| Gender, Male/Female | 153/161 | 15/11 | 0.380b | 103/139 | 29/26 | 0.171b | 0.675b |
| ApoE-e4, N/P | 223/84 | 20/5 | 0.385b | 83/151 | 27/27 |
|
|
| Cohort, ADNI/ANM | 210/104 | 17/9 | 0.876b | 143/99 | 32/23 | 0.902b | 0.536b |
|
| |||||||
| Count | 316 | 24 | 246 | 51 | |||
| Age, years | 75.0 ± 5.8 | 75.3 ± 4.6 | 0.756a | 75.5 ± 7.0 | 76.3 ± 7.1 | 0.493a | 0.553a |
| Education, years | 14.4 ± 4.3 | 12.8 ± 5.6 | 0.205a | 12.0 ± 4.8 | 12.4 ± 5.0 | 0.530a | 0.756a |
| MMSE score | 29.2 ± 1.1 | 28.8 ± 1.4 | 0.168a | 21.8 ± 3.7 | 24.4 ± 2.7 |
|
|
| Gender, Male/Female | 155/161 | 13/11 | 0.629b | 105/141 | 27/24 | 0.180b | 0.921b |
| ApoE-e4, N/P | 225/87 | 18/5 | 0.524b | 86/151 | 24/27 | 0.156b |
|
| Cohort, ADNI/ANM | 213/103 | 14/10 | 0.363b | 144/102 | 31/20 | 0.767b | 0.840b |
p value in bold indicates statistically significant difference
Continuous data is represented as mean ± standard deviation, AD Alzheimer’s disease, CTL control subjects, ApoE apolipoprotein E, N/P negative/positive for at least one e4 allele, MMSE mini mental state examination, ADNI/ANM Alzheimer’s disease Neuroimaging Initiative/AddNeuroMed
aIndependent-samples t test
bPearson χ2
Subjects’ characteristics in MCI prediction: comparison between correctly/incorrectly classified subjects
| MCI prediction | MCI-s subjects | MCI-p subjects | Incorrect-predicted MCI-s versus MCI-p | |||||
|---|---|---|---|---|---|---|---|---|
| Correct-predicted | Incorrect-predicted |
| Correct-predicted | Incorrect-predicted |
|
| ||
| Uncorrected model | Count | 219 | 141 | 59 | 26 | |||
| Age, years | 73.6 ± 7.1 | 77.0 ± 6.1 |
| 75.0 ± 6.9 | 73.1 ± 5.3 | 0.220a |
| |
| Education, years | 13.8 ± 4.6 | 14.1 ± 4.7 | 0.582a | 13.8 ± 4.4 | 13.7 ± 3.8 | 0.820a | 0.651a | |
| MMSE score | 27.4 ± 1.7 | 26.8 ± 1.6 |
| 26.5 ± 1.9 | 26.6 ± 1.6 | 0.802a | 0.682a | |
| Gender, Male/Female | 144/75 | 75/66 |
| 35/24 | 15/11 | 0.888 | 0.672 | |
| ApoE-e4, N/P | 118/87 | 65/71 | 0.077 | 22/36 | 8/16 | 0.694 | 0.190 | |
| Cohort, ADNI/ANM | 151/68 | 109/32 | 0.084 | 44/15 | 18/8 | 0.609 | 0.375 | |
| Covariate model | Count | 219 | 141 | 60 | 25 | |||
| Age, years | 74.7 ± 7.1 | 75.3 ± 6.6 | 0.419a | 74.3 ± 7.0 | 74.6 ± 5.0 | 0.852a | 0.635a | |
| Education, years | 13.8 ± 4.6 | 14.2 ± 4.8 | 0.394a | 13.9 ± 4.4 | 13.7 ± 3.9 | 0.853a | 0.614a | |
| MMSE score | 27.4 ± 1.7 | 26.8 ± 1.7 |
| 26.6 ± 1.9 | 26.4 ± 1.6 | 0.740a | 0.383a | |
| Gender, Male/Female | 149/70 | 70/71 |
| 37/23 | 13/12 | 0.409 | 0.828 | |
| ApoE-e4, N/P | 122/83 | 61/75 |
| 20/39 | 10/13 | 0.418 | 0.902 | |
| Cohort, ADNI/ANM | 150/69 | 110/31 | 0.050 | 43/17 | 19/6 | 0.682 | 0.824 | |
| Detrended model | Count | 225 | 135 | 63 | 22 | |||
| Age, years | 75.2 ± 7.1 | 74.4 ± 6.6 | 0.273a | 74.1 ± 6.9 | 75.4 ± 4.9 | 0.408a | 0.492a | |
| Education, years | 13.8 ± 4.5 | 14.2 ± 4.8 | 0.478a | 14.0 ± 4.1 | 13.2 ± 4.5 | 0.418T | 0.380a | |
| MMSE score | 27.4 ± 1.7 | 26.7 ± 1.7 |
| 26.5 ± 1.9 | 26.6 ± 1.6 | 0.775a | 0.803a | |
| Gender, Male/Female | 154/71 | 65/70 |
| 39/24 | 11/11 | 0.329 | 0.872 | |
| ApoE-e4, N/P | 127/83 | 56/75 |
| 40/22 | 12/8 | 0.715 | 0.817 | |
| Cohort, ADNI/ANM | 156/69 | 104/31 | 0.114 | 46/17 | 16/6 | 0.979 | 0.659 | |
p value in bold indicates statistically significant difference
Continuous data is represented as mean ± SD, MCI mild cognitive impairment, MCI-p progressive MCI, MCI-s stable MCI, ApoE apolipoprotein E, N/P negative/positive for at least one e4 allele, MMSE mini mental state examination, ADNI/ANM Alzheimer’s disease Neuroimaging Initiative/AddNeuroMed
aIndependent-samples t test
bPearson χ2